These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 18714348)

  • 1. Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets.
    Martin KJ; Patrick DR; Bissell MJ; Fournier MV
    PLoS One; 2008 Aug; 3(8):e2994. PubMed ID: 18714348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers.
    Liu D
    Breast Cancer Res Treat; 2020 Aug; 183(1):95-105. PubMed ID: 32601968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction.
    Liu D; Zhou K
    Clin Breast Cancer; 2020 Feb; 20(1):41-50.e8. PubMed ID: 31547956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and Therapeutic Significance of Adhesion-regulating Molecule 1 in Estrogen Receptor-positive Breast Cancer.
    Wu W; Zhong J; Chen J; Niu P; Ding Y; Han S; Xu J; Dai L
    Clin Breast Cancer; 2020 Apr; 20(2):131-144.e3. PubMed ID: 31669266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A matrisome RNA signature from early-pregnancy mouse mammary fibroblasts predicts distant metastasis-free breast cancer survival in humans.
    Ibrahim AM; Bilsland A; Rickelt S; Morris JS; Stein T
    Breast Cancer Res; 2021 Sep; 23(1):90. PubMed ID: 34565423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.
    Mook S; Schmidt MK; Viale G; Pruneri G; Eekhout I; Floore A; Glas AM; Bogaerts J; Cardoso F; Piccart-Gebhart MJ; Rutgers ET; Van't Veer LJ;
    Breast Cancer Res Treat; 2009 Jul; 116(2):295-302. PubMed ID: 18661261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An ER-associated miRNA signature predicts prognosis in ER-positive breast cancer.
    Zhou X; Wang X; Huang Z; Xu L; Zhu W; Liu P
    J Exp Clin Cancer Res; 2014 Nov; 33(1):94. PubMed ID: 25373603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response.
    Ertel A; Dean JL; Rui H; Liu C; Witkiewicz AK; Knudsen KE; Knudsen ES
    Cell Cycle; 2010 Oct; 9(20):4153-63. PubMed ID: 20948315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data.
    Haricharan S; Bainbridge MN; Scheet P; Brown PH
    Breast Cancer Res Treat; 2014 Jul; 146(1):211-20. PubMed ID: 24839032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients.
    Mark KMK; Varn FS; Ung MH; Qian F; Cheng C
    BMC Cancer; 2017 May; 17(1):306. PubMed ID: 28464832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer.
    Teschendorff AE; Miremadi A; Pinder SE; Ellis IO; Caldas C
    Genome Biol; 2007; 8(8):R157. PubMed ID: 17683518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of a 92-probe signature in breast cancer.
    Akter S; Choi TG; Nguyen MN; Matondo A; Kim JH; Jo YH; Jo A; Shahid M; Jun DY; Yoo JY; Nguyen NN; Seo SW; Ali L; Lee JS; Yoon KS; Choe W; Kang I; Ha J; Kim J; Kim SS
    Oncotarget; 2015 Jun; 6(17):15662-80. PubMed ID: 25883221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of estrogen receptor positive primary breast cancers.
    Yau C; Benz CC
    Breast Cancer Res; 2008; 10(4):R61. PubMed ID: 18631401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
    Lehmann BD; Ding Y; Viox DJ; Jiang M; Zheng Y; Liao W; Chen X; Xiang W; Yi Y
    BMC Cancer; 2015 Mar; 15():179. PubMed ID: 25886164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOXM1 cistrome predicts breast cancer metastatic outcome better than FOXM1 expression levels or tumor proliferation index.
    Yau C; Meyer L; Benz S; Vaske C; Scott G; Egan B; Labhart P; Pourmand N; Benz CC
    Breast Cancer Res Treat; 2015 Nov; 154(1):23-32. PubMed ID: 26456572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A qualitative transcriptional signature to reclassify histological grade of ER-positive breast cancer patients.
    Li J; Jiang W; Liang Q; Liu G; Dai Y; Zheng H; Yang J; Cai H; Zheng G
    BMC Genomics; 2020 Apr; 21(1):283. PubMed ID: 32252627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel MAPK-microRNA signature is predictive of hormone-therapy resistance and poor outcome in ER-positive breast cancer.
    Miller PC; Clarke J; Koru-Sengul T; Brinkman J; El-Ashry D
    Clin Cancer Res; 2015 Jan; 21(2):373-85. PubMed ID: 25370469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A gene-expression signature as a predictor of survival in breast cancer.
    van de Vijver MJ; He YD; van't Veer LJ; Dai H; Hart AA; Voskuil DW; Schreiber GJ; Peterse JL; Roberts C; Marton MJ; Parrish M; Atsma D; Witteveen A; Glas A; Delahaye L; van der Velde T; Bartelink H; Rodenhuis S; Rutgers ET; Friend SH; Bernards R
    N Engl J Med; 2002 Dec; 347(25):1999-2009. PubMed ID: 12490681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.
    Schroth W; Winter S; Büttner F; Goletz S; Faißt S; Brinkmann F; Saladores P; Heidemann E; Ott G; Gerteis A; Alscher MD; Dippon J; Schwab M; Brauch H; Fritz P
    Breast Cancer Res Treat; 2016 Jan; 155(1):85-97. PubMed ID: 26650824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A potential prognostic long non-coding RNA signature to predict metastasis-free survival of breast cancer patients.
    Sun J; Chen X; Wang Z; Guo M; Shi H; Wang X; Cheng L; Zhou M
    Sci Rep; 2015 Nov; 5():16553. PubMed ID: 26549855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.